作者: Mario Airoldi , Antonella De Stefani , Sara Marchionatti , Fulvia Pedani , Pietro Gabriele
DOI: 10.1002/HED.1034
关键词:
摘要: Background We have shown that rIL-2 administration in recurrent head and neck cancers induces a tumor-specific T-lymphocyte reactivity tumor regression; pilot study we safe effective of rIL2 after cisplatin + 5-fluorouracil. Long-term results are not known. Methods Thirty patients with recurrent-persistent cancer were treated (100 mg-m2) d.1,5-fluorouracil (1 gr-m2-d c.i. 96 h), SQ (4.5 M IU day 8 to 12 15 19) every 3 weeks. Results The overall response rate was 53.3% (95% CI; 34.4–72.3%): 26.6% complete (CR) (8 patients) partial (PR) patients); 6 had SD (20%), PD (26.6%). The median follow-up 36 months (range, 28–44).The CR duration is 16.2 (8.5–39+); the survival this group has been reached. PR 7.2 (3–10); 13.3 (10–26). 14 months. Conclusions The most impressive finding very long CRs patients. This outcome reported other IL-2 therapy. © 2001 John Wiley & Sons, Inc. Head Neck 23: 298–304, 2001.